Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis

Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were over...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Xavier, Withers, Barbara, Jabbour, Andrew, Milliken, Sam, Kotlyar, Eugene, Fay, Keith, Ma, David, Muthiah, Kavitha, Hamad, Nada, Dodds, Anthony, Bart, Nikki, Keogh, Anne, Hayward, Chris, Macdonald, Peter, Moore, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828809/
https://www.ncbi.nlm.nih.gov/pubmed/36266066
http://dx.doi.org/10.1111/imj.15926
_version_ 1784867350421438464
author Brennan, Xavier
Withers, Barbara
Jabbour, Andrew
Milliken, Sam
Kotlyar, Eugene
Fay, Keith
Ma, David
Muthiah, Kavitha
Hamad, Nada
Dodds, Anthony
Bart, Nikki
Keogh, Anne
Hayward, Chris
Macdonald, Peter
Moore, John
author_facet Brennan, Xavier
Withers, Barbara
Jabbour, Andrew
Milliken, Sam
Kotlyar, Eugene
Fay, Keith
Ma, David
Muthiah, Kavitha
Hamad, Nada
Dodds, Anthony
Bart, Nikki
Keogh, Anne
Hayward, Chris
Macdonald, Peter
Moore, John
author_sort Brennan, Xavier
collection PubMed
description Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.
format Online
Article
Text
id pubmed-9828809
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-98288092023-01-10 Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis Brennan, Xavier Withers, Barbara Jabbour, Andrew Milliken, Sam Kotlyar, Eugene Fay, Keith Ma, David Muthiah, Kavitha Hamad, Nada Dodds, Anthony Bart, Nikki Keogh, Anne Hayward, Chris Macdonald, Peter Moore, John Intern Med J Brief Communications Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late‐stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group. John Wiley & Sons Australia, Ltd 2022-10-20 2022-10 /pmc/articles/PMC9828809/ /pubmed/36266066 http://dx.doi.org/10.1111/imj.15926 Text en © 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Brennan, Xavier
Withers, Barbara
Jabbour, Andrew
Milliken, Sam
Kotlyar, Eugene
Fay, Keith
Ma, David
Muthiah, Kavitha
Hamad, Nada
Dodds, Anthony
Bart, Nikki
Keogh, Anne
Hayward, Chris
Macdonald, Peter
Moore, John
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
title Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
title_full Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
title_fullStr Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
title_full_unstemmed Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
title_short Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
title_sort efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac al amyloidosis
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828809/
https://www.ncbi.nlm.nih.gov/pubmed/36266066
http://dx.doi.org/10.1111/imj.15926
work_keys_str_mv AT brennanxavier efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT withersbarbara efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT jabbourandrew efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT millikensam efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT kotlyareugene efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT faykeith efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT madavid efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT muthiahkavitha efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT hamadnada efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT doddsanthony efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT bartnikki efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT keoghanne efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT haywardchris efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT macdonaldpeter efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis
AT moorejohn efficacyofbortezomibcyclophosphamideanddexamethasoneincardiacalamyloidosis

Ejemplares similares